2387-23-7 | N,N'-Dicyclohexylurea

Packsize	Purity	Availability	Price	Discounted Price
5g	95%	in stock	$14.00	$10.00
10g	95%	in stock	$26.00	$18.00
25g	95%	in stock	$38.00	$27.00
100g	95%	in stock	$86.00	$60.00
500g	95%	in stock	$249.00	$175.00

Description

• Catalog Number: AB52276
• Chemical Name: N,N'-Dicyclohexylurea
• CAS Number: 2387-23-7
• Molecular Formula: C13H24N2O
• Molecular Weight: 224.3425
• MDL Number: MFCD00003829
• SMILES: O=C(NC1CCCCC1)NC1CCCCC1

Computed Properties

• Complexity: 196
• Covalently-Bonded Unit Count: 1
• Heavy Atom Count: 16
• Hydrogen Bond Acceptor Count: 1
• Hydrogen Bond Donor Count: 2
• Rotatable Bond Count: 2
• XLogP3: 3

Literature

• Development of Ecom₅₀ and retention index models for nontargeted metabolomics: identification of 1,3-dicyclohexylurea in human serum by HPLC/mass spectrometry.

  Journal of chemical information and modeling 20120525

• (E)-N-Butyl-3-(3,4-dihy-droxy-phen-yl)acryl-amide hemihydrate.

  Acta crystallographica. Section E, Structure reports online 20120301

• Thermal degradation of amorphous glibenclamide.

  European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V 20120101

• Design, synthesis and evaluation of non-urea inhibitors of soluble epoxide hydrolase.

  Bioorganic & medicinal chemistry letters 20120101

• 2,5-Dioxopyrrolidin-1-yl 3-(furan-2-yl)acrylate.

  Acta crystallographica. Section E, Structure reports online 20111101

• (R)-2-Phen-oxy-1-(4-phenyl-2-sulfan-ylidene-1,3-oxazolidin-3-yl)ethanone.

  Acta crystallographica. Section E, Structure reports online 20111001

• Oleic acid induces smooth muscle foam cell formation and enhances atherosclerotic lesion development via CD36.

  Lipids in health and disease 20110101

• Investigation of utilization of nanosuspension formulation to enhance exposure of 1,3-dicyclohexylurea in rats: Preparation for PK/PD study via subcutaneous route of nanosuspension drug delivery.

  Nanoscale research letters 20110101

• In Vitro and In Vivo Study of Poly(ethylene glycol) Conjugated Ibuprofen to Extend the Duration of Action.

  Scientia pharmaceutica 20110101

• Process optimization for the preparation of oligomycin-loaded folate-conjugated chitosan nanoparticles as a tumor-targeted drug delivery system using a two-level factorial design method.

  International journal of nanomedicine 20110101

• The solid state structure and reactivity of NbCl(5) x (N,N'-dicyclohexylurea) in solution: evidence for co-ordinated urea dehydration to the relevant carbodiimide.

  Dalton transactions (Cambridge, England : 2003) 20100814

• Hypericins as potential leads for new therapeutics.

  International journal of molecular sciences 20100101

• Synthesis, characterization, and biological evaluation of poly(L-γ-glutamyl-glutamine)- paclitaxel nanoconjugate.

  International journal of nanomedicine 20100101

• Targeting the OB-Folds of Replication Protein A with Small Molecules.

  Journal of nucleic acids 20100101

• Spacer/Linker based synthesis and biological evaluation of mutual prodrugs as antiinflammatory agents.

  Indian journal of pharmaceutical sciences 20100101

• 2-(2-Chloro-3-quinol-yl)-3-phenyl-thia-zolidin-4-one.

  Acta crystallographica. Section E, Structure reports online 20091101

• 4-Methyl-3-(2-phenoxy-acet-yl)-5-phenyl-1,3,4-oxadiazinan-2-one.

  Acta crystallographica. Section E, Structure reports online 20090701

• In vitro biologic activities of the antimicrobials triclocarban, its analogs, and triclosan in bioassay screens: receptor-based bioassay screens.

  Environmental health perspectives 20080901

• Second-generation difluorinated cyclooctynes for copper-free click chemistry.

  Journal of the American Chemical Society 20080827

• Hydrolysis of cis- and trans-epoxyeicosatrienoic acids by rat red blood cells.

  The Journal of pharmacology and experimental therapeutics 20080701

• Oral delivery of 1,3-dicyclohexylurea nanosuspension enhances exposure and lowers blood pressure in hypertensive rats.

  Basic & clinical pharmacology & toxicology 20080501

• Orally bioavailable potent soluble epoxide hydrolase inhibitors.

  Journal of medicinal chemistry 20070809

• Novel dexamethasone-HPMA copolymer conjugate and its potential application in treatment of rheumatoid arthritis.

  Arthritis research & therapy 20070101

• Novel peptide sequence ('IQ-tag') with high affinity for NIR fluorochromes allows protein and cell specific labeling for in vivo imaging.

  PloS one 20070101

• 14,15-Dihydroxyeicosatrienoic acid activates peroxisome proliferator-activated receptor-alpha.

  American journal of physiology. Heart and circulatory physiology 20060101

• Structure-activity relationships of dinucleotides: Potent and selective agonists of P2Y receptors.

  Purinergic signalling 20050601

• Effect of soluble epoxide hydrolase inhibition on epoxyeicosatrienoic acid metabolism in human blood vessels.

  American journal of physiology. Heart and circulatory physiology 20041201

• Role of EETs in regulation of endothelial permeability in rat lung.

  American journal of physiology. Lung cellular and molecular physiology 20040201

• Investigation of the active constituents of Portulaca oleraceae L. (Portulacaceae) growing in Jordan.

  Pakistan journal of pharmaceutical sciences 20040101

• Impurity profile study of repaglinide.

  Journal of pharmaceutical and biomedical analysis 20030714

• Rapid determination of soluble epoxide hydrolase inhibitors in rat hepatic microsomes by high-performance liquid chromatography with electrospray tandem mass spectrometry.

  Analytical biochemistry 20011215

• Pathways of epoxyeicosatrienoic acid metabolism in endothelial cells. Implications for the vascular effects of soluble epoxide hydrolase inhibition.

  The Journal of biological chemistry 20010504

• Soluble epoxide hydrolase regulates hydrolysis of vasoactive epoxyeicosatrienoic acids.

  Circulation research 20001124